"We are very excited to partner with a great organization like Crystal Research. With fewer sell-side firms capable and willing to provide research coverage for small and microcap stocks, we see tremendous value in independent research. After seeing Jeff and his team work with a few of our clients, we were extremely impressed with their diligent process and comprehensive reports. Forming this partnership allows us to leverage our collective strengths to help investors fully understand our client's stories and to increase investor and media awareness and interest in our client's companies."

This morning, Crystal Research's CEO Jeff Kraws was invited to participate in a roundtable discussion to analyze how investors should be reacting to President Obama's State of the Union address. The segment was hosted by Thomson Reuters' Rhonda Schaffler and also featured David Joy, Chief Market Strategist of Ameriprise Financial, and Craig Irwin, Senior Vice President at Wedbush Securities.

If you are at the OneMedForum conference in San Francisco today, we invite you to join us for the “Special Session: Fund Managers Unplugged” panel occurring at 4 PM at the Sir Francis Drake Hotel.

Crystal Research Associates' CEO Jeffrey Kraws will be moderating the discussion, accompanied by panelists Mr. Dennis J. Purcell, Senior Managing Partner at Aisling Capital with approximately $1.7 billion in assets under management; Dr. J. Misha Petkevich, Co-founder of BladeRock Capital and former Chairman and CEO of The Petkevich Group, LLC; and Mr. William S. Slattery, Partner at Deerfield Management Company, L.P. where he focuses on biotechnology investments.

CEO Jeff Kraws selected to moderate a Special Session "Fund Managers Unplugged" at the 6th Annual OneMedForum Conference in San Francisco on Wednesday, January 9, 2013.

From all of us here at Crystal Research Associates, we would like to wish you and your family a joyful holiday season and a prosperous new year!

Partnership with OneMedPlace provides research and expanded media coverage to client companies

Crystal Research Associates' August 2012 nanotechnology update is now available here. This report is part of our ongoing coverage to our initial comprehensive industry review, Nanotechnology and the Built Environment: The Transition to Green Infrastructure, published November 2011 and available at www.crystalra.com.

CNBC today published an article wherein the founder of Vanguard Group discussed his view on the necessity of investing in equities, which while higher risk, offer the potential for higher reward.

Amid a depressed global economic environment, investments in cleantech were estimated to total $1.6 billion in the second quarter 2012, down from $1.9 billion in the first quarter 2012and $2.1 billion in the comparable year-ago period (second quarter 2011). Factors driving down investment include global economic uncertainties as well as political opposition to government subsidies in areas such as solar and wind power and electric vehicle development. A depressed U.S. IPO market is further hampering greentech funding efforts. 

Novel biotech company AtheroNova Inc. (AHRO-OTC) made a significant news announcement last week when it reported the receipt of a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its main patent. The Notice of Allowance entailed written communication from the USPTO to AtheroNova that the Company’s primary patent was allowable. A Notice of Allowance specifies the amount of issue and/or publication fees that are due within three months in order to avoid abandonment of the applications (Source: USPTO). Accordingly, AtheroNova expects to announce the official patent issuance within the next few months once the registration process is complete.  

This morning, Crystal Research CEO Jeff Kraws spoke with Reuters' Rhonda Schaffler about winners and losers of today's landmark Supreme Court ruling upholding Obamacare's individual mandate. Mr. Kraws discussed specific stocks to watch as well as sector trends for healthcare insurers, hospitals, pharma and biotech companies, medical records, medical schools, generics, and medical device companies, among others.

Crystal Research Associates' Director of Healthcare, David H. Talbot, discusses research trends in small-cap stocks on Seeking Alpha. Article excerpt below; click here for a link to the full text.

As researchers have recently emphasized, governments have a significant role and responsibility for providing long-term support for renewable energy, smart grid, and other future “sustainable city” initiatives. The price of renewable energies and associated technologies are too high to appeal to investors without government support. Mechanisms such as incentives, feed‐in‐tariffs, tax‐breaks, rebates, and other financial instruments are critical.

With that in mind, we have released a 12-page report that expands upon several U.S. policies expected to further market adoption of sustainable, nanotechnology-driven technologies. The report, Continuing Coverage of Nanotechnology and the Built Environment (available here), is the latest update to our base report, Nanotechnology and the Built Environment: The Transition to Green Infrastructure. This update is part of a series of “continuing coverage” reports from Crystal Research Associates that detail innovations in nanotechnology and their impact on our infrastructure, building, and construction markets.